In this episode Michael Kruidenier chats with Michael O'Donoghue the Head of Site in New Hampshire US, where Quay's latest 50,000 sq ft facility is preparing for pharmaceutical development and clinical manufacturing.

In this episode, Chris Davies from Oxford Global discusses with Maura McArdle how Covid has changed how Quay reaches out to potential new clients and what to expect from Quay's up-coming webinar on Lipid based drug delivery.

In this episode, Chris Davies from Oxford Global discusses with Maura McArdle how Covid has changed how Quay reaches out to potential new clients and what to expect from Quay's up-coming webinar on Lipid based drug delivery.

In this episode Maura McArdle and Audrey Vardy from Quay Pharma, discuss what is involved in a typical pharmaceutical development for clinical trials and what differentiates Quay Pharma from other CDMO's.

In this episode Maura McArdle and Audrey Vardy from Quay Pharma, discuss what is involved in a typical pharmaceutical development for clinical trials and what differentiates Quay Pharma from other CDMO's.

In this episode, Dr. Ivan Langan & Michael Kruidenier from Quay talk to Adam Andersen from Informa Markets. They discuss how they are adapting to Covid-19 and the new and emerging virtual conference world.

In this episode, Dr. Ivan Langan & Michael Kruidenier from Quay talk to Adam Andersen from Informa Markets. They discuss how they are adapting to Covid-19 and the new and emerging virtual conference world.

In this episode, Audrey Vardy talks to Mike Card a KTP Advisor about the Knowledge Transfer Partnership programme.

In this episode, Audrey Vardy talks to Mike Card a KTP Advisor about the Knowledge Transfer Partnership programme.

Maura McArdle and Audrey Vardy share a discussion on Quay's Pre Clinical service and expertise.